EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry

Jesse M Tettero iD, Naveen Dakappagari, Maaike E Heidinga, Yvonne Oussoren-Brockhoff, Diana Hanekamp, Anil Pahuja, Kerri Burns, Pavinder Kaur, Zeni Alfonso, Vincent H J van der Velden iD, Jeroen G Te Marvelde, Willemijn Hobo und 5 weitere

Cytometry Part B: Clinical Cytometry · 2023-11 · 104 (6) · 426-439

DOI: 10.1002/cyto.b.22144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 28.09.2023. Verfasst von Jesse M Tettero und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: KWF Kankerbestrijding, Navigate BioPharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Measurable residual disease (MRD) assessed by multiparametric flow cytometry (MFC) has gained importance in clinical decision‐making for acute myeloid leukemia (AML) patients. However, complying with the recent In Vitro Diagnostic Regulations (IVDR) in Europe and Food and Drug Administration (FDA) guidance in the United States requires rigorous validation prior to their use in investigational clinical trials and diagnostics. Validating AML MRD‐MFC assays poses challenges due to the unique underlying disease biology and paucity of patient specimens. In this study, we describe an experimental framework for validation that meets regulatory expectations.

Methods

Our validation efforts focused on evaluating assay accuracy, analytical specificity, analytical and functional sensitivity (limit of blank (LoB), detection (LLoD) and quantitation (LLoQ)), precision, linearity, sample/reagent stability and establishing the assay background frequencies.

Results

Correlation between different MFC methods was highly significant ( r = 0.99 for %blasts and r = 0.93 for %LAIPs). The analysis of LAIP specificity accurately discriminated from negative control cells. The assay demonstrated a LoB of 0.03, LLoD of 0.04, and LLoQ of 0.1%. Precision experiments yielded highly reproducible results (Coefficient of Variation

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansFlow CytometryNeoplasm, ResidualImmunophenotyping

Stichwörter der Autor:innen

assay validationflow-cytometrymeasurable residual disease

Autor:innen und Institutionen

  • Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
  • Navigate BioPharma (a Novartis Subsidiary), Carlsbad, California, USA.
  • Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Laboratory Medicine-Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Jesse M Tettero, Vincent H J van der Velden, Costa Bachas, Jacqueline Cloos

Förderung

  • KWF Kankerbestrijding
  • Navigate BioPharma

Zitieren

APA

Tettero, J. M., Dakappagari, N., Heidinga, M. E., Oussoren-Brockhoff, Y., Hanekamp, D., Pahuja, A., Burns, K., Kaur, P., Alfonso, Z., van der Velden, V. H. J., Te Marvelde, J. G., Hobo, W., Slomp, J., Bachas, C., Kelder, A., Nguyen, K., & Cloos, J. (2023). Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry. Cytometry Part B: Clinical Cytometry, 104(6), 426-439. https://doi.org/10.1002/cyto.b.22144

Vancouver

Tettero JM, Dakappagari N, Heidinga ME, Oussoren-Brockhoff Y, Hanekamp D, Pahuja A, et al. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry. Cytometry Part B: Clinical Cytometry. 2023;104(6):426-439. doi:10.1002/cyto.b.22144

BibTeX
@article{Tettero2023,
  author = {Tettero, Jesse M and Dakappagari, Naveen and Heidinga, Maaike E and Oussoren-Brockhoff, Yvonne and Hanekamp, Diana and Pahuja, Anil and Burns, Kerri and Kaur, Pavinder and Alfonso, Zeni and van der Velden, Vincent H J and Te Marvelde, Jeroen G and Hobo, Willemijn and Slomp, Jennichjen and Bachas, Costa and Kelder, Angele and Nguyen, Kevin and Cloos, Jacqueline},
  title = {Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2023},
  volume = {104},
  number = {6},
  pages = {426--439},
  doi = {10.1002/cyto.b.22144}
}
Kostenlos starten →